» Articles » PMID: 9032887

The Hemagglutination Inhibition Antibody Responses to an Inactivated Influenza Vaccine Among Healthy Adults: with Special Reference to the Prevaccination Antibody and Its Interaction with Age

Overview
Journal Vaccine
Date 1996 Dec 1
PMID 9032887
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

The immunogenicity of the trivalent split-virus influenza vaccine was investigated among 70 healthy adults (mean age: 48.5, range: 36-68). The vaccine antigens were: A/Yamagata/32/89 (H1N1); A/Beijing/352/89 (H3N2); and B/Bangkok/163/90. Regarding the entire sample, the vaccine induced a tenfold or more rise on the average in the hemagglutination inhibition (HAI) antibody to each antigen. The response rates (greater than or equal to a fourfold rise) were about 90% or more among those with a prevaccination titer < or = 1:64 (equivalent to < or = 1:16 on the Western scale; in Japan, the HAI titers are expressed by the final, and not the initial, dilution of the serum; from hereon our findings will be expressed using the Japanese scale), whereas they were 0-50% at > or = 1:128. Thus, the prevaccination titer was negatively associated with antibody induction. The achievement rates (postvaccination titer > or = 1:128) among those with a prevaccination titer < 1:16 remained at 48-68%. Regarding the analysis of variance, a significant effect on antibody induction was indicated for the prevaccination titer (P < or = 0.002), but not for age (P > or = 0.425). The interaction between the prevaccination titer and age was significant for A/Yamagata (P = 0.030), while it was also suggestive for A/Beijing (P = 0.054): as age increased, those with no preexisting antibody (< 1:16) showed greater titer rises, in contrast to the smaller rises among those with a titer > or = 1:16. Based on the attack survey conducted separately, the vaccine efficacy on influenza-like illnesses with fever < or = 37 degrees C and > or = 37.5 degrees C was calculated to be 16% (95% confidence interval: -66% to 57%) and 37% (-55% to 74%), respectively.

Citing Articles

Investigating the Interaction between Negative Strand RNA Viruses and Their Hosts for Enhanced Vaccine Development and Production.

Mara K, Dai M, Brice A, Alexander M, Tribolet L, Layton D Vaccines (Basel). 2021; 9(1).

PMID: 33477334 PMC: 7830660. DOI: 10.3390/vaccines9010059.


Impact of Vitamin D Supplementation on Influenza Vaccine Response and Immune Functions in Deficient Elderly Persons: A Randomized Placebo-Controlled Trial.

Goncalves-Mendes N, Talvas J, Duale C, Guttmann A, Corbin V, Marceau G Front Immunol. 2019; 10:65.

PMID: 30800121 PMC: 6375825. DOI: 10.3389/fimmu.2019.00065.


Different Repeat Annual Influenza Vaccinations Improve the Antibody Response to Drifted Influenza Strains.

Plant E, Fredell L, Hatcher B, Li X, Chiang M, Kosikova M Sci Rep. 2017; 7(1):5258.

PMID: 28701762 PMC: 5507920. DOI: 10.1038/s41598-017-05579-4.


Immunogenicity and Safety of Trivalent Split Influenza Vaccine in Healthy Korean Adults with Low Pre-Existing Antibody Levels: An Open Phase I Trial.

Kang K, Han S, Hong T, Jeon S, Paek J, Kang J Yonsei Med J. 2016; 57(6):1354-60.

PMID: 27593862 PMC: 5011266. DOI: 10.3349/ymj.2016.57.6.1354.


Trivalent influenza vaccine-induced antibody response to circulating influenza a (H3N2) viruses in 2010/11 and 2011/12 seasons.

Hiroi S, Morikawa S, Nakata K, Maeda A, Kanno T, Irie S Hum Vaccin Immunother. 2015; 11(2):386-90.

PMID: 25692378 PMC: 4514160. DOI: 10.1080/21645515.2015.1009338.